



## NON SMALL CELL LUNG CANCER MARKET ANALYSIS FOR TARGETED THERAPIES IN TURKEY

Aysen Senturk<sup>1</sup>

<sup>1</sup>AXEL Health Solutions, Ankara, Turkey

### OBJECTIVES

NSCLC accounts for 80% of all lung cancers. As molecular pathways in NSCLC and mutations in these pathways are revealed, targeted therapies specific to these mutations have been developed. These therapies, has led to an increase in the life span, progression free survival and quality of life for metastatic patients. The incidence rate of NSCLC in Turkey is 59.3 in 100,000 in men while 10 in 100,000 in women. The purpose of this study is to analyze the targeted therapies in NSCLC market and to identify their registration and reimbursement status.

### METHODS


The study was undertaken from the Turkish health care payer perspective (SSI). An Excel sheet was formed to calculate the ratios and results. Resource utilization data were obtained from MoH List of Registered Drugs June 2018, RxMediapharma, SSI Health Implementation Guideline Annex 4/A and Rx Media Pharma 2018.

### FINDINGS


**Table 1: NSCLC Market Registration & Reimbursement Status**

Group	Active Ingredients	Company	Registration Status	Reimbursement Status
ALK	Crizotinib	Pfizer	✓	✓
	Ceritinib	Novartis	✓	✓
	Alectinib	Roche	✓	✓
EGFR	Brigatinib	Takeda	ongoing process	×
	Erlotinib	Roche	✓	✓
	Afatinib	Boehringer Ingelheim	✓	✓
	Gefitinib	Astra Zeneca	✓	✓
	Osimertinib	Astra Zeneca	✓	✓
	Necitumumab	Lilly	×	×
VEGF	Bevacizumab	Roche	✓	✓
	Ramucirumab	Lilly	✓	×
PDL-1	Nivolumab	BMS	✓	✓
	Pembrolizumab	MSD	✓	×
	Durvalumab	Astra Zeneca	ongoing process	×
BRAF	Atezolizumab	Roche	✓	×
	Dabrafenib	Novartis	✓	✓
	Trametinib	Novartis	✓	✓


**Graphic 1: Registered & Reimbursed Share of NSCLC Products**



**Graphic 2 : Reimbursement Way of NSCLC Products**



**Graphic 3 : Reimbursement Duration of NSCLC Products**



### RESULTS

There are 17 targeted NSCLC therapies in global market. These are subclassified as ALK, EGFR, VEGF, BRAF, PDL-1 mutation drugs. 14 of them (82%) are registered in Turkey. 2 of them are still in the registration process. 11 of these drugs (65%) are reimbursed by SSI. 5 of these reimbursed therapies (45%) were granted reimbursement via Managed Entry Agreements by Alternative Reimbursement Committee. Maximum duration of the reimbursement evaluation process was 22 months and the shortest duration was 3 months. Main companies in this therapeutic area respectively are Roche, Novartis and Astra Zeneca.

### CONCLUSION

New targeted therapies for NSCLC constitute a significant market in Turkey and is one of the most reimbursement granted therapeutic groups in 2018.